It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gingipains are protease virulence factors produced by Porphyromonas gingivalis, a Gram-negative bacterium best known for its role in chronic periodontitis. Gingipains were recently identified in the middle temporal gyrus of postmortem Alzheimer’s disease (AD) brains, where gingipain load correlated with AD diagnosis and tau and ubiquitin pathology. Since AD and Parkinson’s disease (PD) share some overlapping pathologic features, including nigral pathology and Lewy bodies, the current study explored whether gingipains are present in the substantia nigra pars compacta of PD brains. In immunohistochemical techniques and multi-channel fluorescence studies, gingipain antigens were abundant in dopaminergic neurons in the substantia nigra of both PD and neurologically normal control brains. 3-dimensional reconstructions of Lewy body containing neurons revealed that gingipains associated with the periphery of alpha-synuclein aggregates but were occasionally observed inside aggregates. In vitro proteomic analysis demonstrated that recombinant alpha-synuclein is cleaved by lysine-gingipain, generating multiple alpha-synuclein fragments including the non-amyloid component fragments. Immunogold electron microscopy with co-labeling of gingipains and alpha-synuclein confirmed the occasional colocalization of gingipains with phosphorylated (pSER129) alpha-synuclein. In dopaminergic neurons, gingipains localized to the perinuclear cytoplasm, neuromelanin, mitochondria, and nucleus. These data suggest that gingipains localize in dopaminergic neurons in the substantia nigra and interact with alpha-synuclein.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Inc., Previously Cortexyme, South San Francisco, USA; Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956)
2 The University of Auckland, NeuroValida, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); The University of Auckland, Department of Anatomy and Medical Imaging, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
3 The University of Auckland, NeuroValida, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); The University of Auckland, Department of Pharmacology and Clinical Pharmacology, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343)
4 Inc., Previously Cortexyme, South San Francisco, USA (GRID:grid.9654.e); Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956); Inc., Lighthouse Pharmaceuticals, San Francisco, USA (GRID:grid.168010.e)